City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News ...

The first patient with locally advanced rectal cancer has been enrolled onto the phase 1b proof-of-concept FORTRESS study which is evaluating the investigative immunotherapy NG-350A, according to data ...

Future research should evaluate long-term outcomes in patients with rectal cancer. References Mohammed H, Gabra IM, Halawa N, Naeem S, Ogah CO, Nath TS.

But in 2024, she published encouraging results from a small study of people with rectal cancer, in which all 42 patients who got the checkpoint inhibitor, dostarlimab, as a monthly infusion became ...

It was Stage 3 rectal cancer that had already spread to her lymph nodes. At the time of diagnosis, she had a 7-month old baby, a 2-year-old and a 6-year-old. "None of this is normal," she says.

Now, “what we just published shows two things. Those rectal cancer patients remain at 100%, at almost 50 patients responding completely, but it’s durable.

Organ preservation has become an attractive alternative to patients with rectal cancer who achieve a clinical complete response (cCR) after neoadjuvant therapy. 1 - 3 Strict surveillance programs ...

The researchers assessed data on 788 patients with colon cancer (mean age, 58.5 years) from an institutional database and 77,790 patients from the National Cancer Database (mean age, 59.3 years).

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.